LENZ Therapeutics (LENZ) Gains from Investment Securities (2023 - 2024)

LENZ Therapeutics' (LENZ) quarterly Gains from Investment Securities came in at $1.0 million in Q1 2024, up 6443.75% year-on-year from $16000.0 in Q2 2023, and up 489.22% on a QoQ basis from -$269000.0 in Q4 2023.

LENZ Therapeutics (LENZ) Gains from Investment Securities (2023 - 2024) Analysis & Trends

LENZ Therapeutics (LENZ) has 2 years of Gains from Investment Securities data on file, last reported at $1.0 million in Q1 2024.

  • On a quarterly basis, Gains from Investment Securities rose 6443.75% year-over-year to $1.0 million in Q1 2024; TTM through Dec 2024 was $1.0 million, a 951.22% increase from a year earlier, with the FY2024 full-year figure at $1.0 million, up 951.22% from the prior year.
  • Gains from Investment Securities for Q1 2024 stood at $1.0 million, up from -$269000.0 in the prior quarter.
  • Over the last five years, Gains from Investment Securities for LENZ reached as high as $1.0 million in Q1 2024 and fell as low as -$269000.0 in Q4 2023.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,222.41 Bn 67,222.13 Bn -
2 Nanobiotix 1,909.44 Bn 1,909.38 Bn -
3 Akari Therapeutics 989.71 Bn 989.71 Bn -
4 BeOne Medicines 471.12 Bn 466.33 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.84 Bn 114.59 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.89 Bn 61.14 Bn 3.31 Bn
7 Belite Bio 62.74 Bn 62.74 Bn -
8 Argenx Se 55.83 Bn 50.64 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.34 Bn 34.34 Bn 959.66 Mn
10 LENZ Therapeutics 180.59 Mn -77.79 Mn 825,000.00

Historic Data

Download Data
DateValue
Mar 31, 2024 1.05 Mn
Mar 31, 2024 1.05 Mn
Dec 31, 2023 -269,000.00
Dec 31, 2023 -269,000.00
Sep 30, 2023 106,000.00
Sep 30, 2023 106,000.00
Jun 30, 2023 24,000.00
Jun 30, 2023 24,000.00
Mar 31, 2023 16,000.00
Mar 31, 2023 16,000.00